Wednesday, 7 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange

Gufic BioSciences Ltd

NSE: GUFICBIO · BSE: 509079 · Pharmaceuticals & Biotechnology · 33 announcements

Share price
₹422.55
Market cap
₹4,237 Cr
Revenue (annual)
₹944.0 Cr
Net profit (annual)
₹64.21 Cr
P/E (TTM)
57.7×Sector 47.3×
Promoter holding
72.50%+0.00% QoQ
FII holding
0.47%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

15:26 IST NSE
Acquisition

Gufic BioSciences Acquisition

Gufic Biosciences clarified its share subscription in Saraswat Co-operative Bank is for regulatory borrower-linkage requirements. The transaction maintains existing credit facilities without changing bank control.

22:53 IST BSE
Acquisition

Gufic BioSciences Acquisition Worth ₹5.75 Cr

Gufic Biosciences approved a ₹5.75 Crore equity investment in Saraswat Co-operative Bank Limited. The move strengthens their existing banking relationship and broader treasury management strategy.

Value
₹5.75 Cr
Execution
Within four months
16:17 IST NSE
Acquisition

Gufic BioSciences Acquisition Worth ₹0.47 Cr

Gufic Biosciences Limited has completed a further investment of ₹0.47 Crore (USD 50,000) in Selvax Pty Ltd. The transaction involved subscribing to 378,350 ordinary shares at AUD 20 cents per share. This strategic investment strengthens Gufic's international portfolio and was finalized on April 28, 2026.

Value
₹0.47 Cr
14:42 IST NSE
Acquisition

Gufic BioSciences Acquisition Worth ₹0.47 Cr

Gufic Biosciences Limited invested USD 50,000 (₹0.47 Crore) to acquire 3,78,350 additional shares in Australian biotech firm Selvax Pty Ltd. This strategic move aims to develop novel immunotherapy treatments for solid tumours. Following this transaction, Gufic's total holding in Selvax reached 16,85,350 shares, strengthening its oncology and biotechnology portfolio.

Value
₹0.47 Cr